Akebia Therapeutics's book value per share for the quarter that ended in Mar. 2026 was €0.09.
During the past 12 months, Akebia Therapeutics's average Book Value Per Share Growth Rate was 8.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 63.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Akebia Therapeutics was 63.80% per year. The lowest was -79.50% per year. And the median was -13.40% per year.
During the past 13 years, the highest P/B Ratio of Akebia Therapeutics was 42.23. The lowest was 0.85. And the median was 3.56.
Akebia Therapeutics (STU:AX9) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Akebia Therapeutics Book Value per Share Related Terms
Akebia Therapeutics Book Value per Share Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AX9 vs TKNO, ORGO, SIGA: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (STU:AX9) has a Book Value per Share of €0.09 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Book Value per Share too high?
Akebia Therapeutics' current Book Value per Share is €0.09. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Book Value per Share compare to TKNO and ORGO?
Akebia Therapeutics' Book Value per Share of €0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Book Value per Share is €0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.10, compared to a current price of €1.22 — trading 10.5% above its estimated fair value. The current Book Value per Share is €0.09. Akebia Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Book Value per Share is €0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued.
The current stock price of €1.22 is trading 10.5% above its estimated GF Value™ of €1.10.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for STU:AX9:
Book Value per Share: €0.09
GF Value™: €1.10 vs. price of €1.22 (10.5% above fair value)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score
Get the complete analysis for STU:AX9
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
